According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
A number of other research analysts have also recently commented on the stock. Piper Jaffray Companies set a $40.00 target price on shares of Tapestry and gave the stock a buy rating in a report on Monday, June 10th. Canaccord Genuity reissued an average rating on shares of Kellogg in a report on Tuesday, June 25th. Finally, BidaskClub cut shares of Virtu Financial from a sell rating to a strong sell rating in a report on Wednesday, June 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Natera currently has a consensus rating of Buy and an average price target of $30.14.
Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, May 9th. The medical research company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The firm had revenue of $66.82 million during the quarter, compared to analysts’ expectations of $66.40 million. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%. Sell-side analysts forecast that Natera will post -2.17 EPS for the current fiscal year.
In related news, insider Jonathan Sheena sold 1,033 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $24.79, for a total value of $25,608.07. Following the completion of the transaction, the insider now owns 240,061 shares in the company, valued at approximately $5,951,112.19. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Chairman Matthew Rabinowitz sold 1,418 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $35,152.22. Following the completion of the transaction, the chairman now owns 1,286,612 shares of the company’s stock, valued at approximately $31,895,111.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,311 shares of company stock valued at $132,287. 9.29% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Focused Wealth Management Inc bought a new position in Natera during the 2nd quarter worth approximately $83,000. Legal & General Group Plc raised its holdings in Natera by 14.5% during the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after purchasing an additional 736 shares during the last quarter. Great West Life Assurance Co. Can raised its holdings in Natera by 136.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after purchasing an additional 3,420 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in Natera by 827.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock worth $163,000 after purchasing an additional 7,047 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its holdings in Natera by 431.9% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 11,867 shares of the medical research company’s stock worth $166,000 after purchasing an additional 9,636 shares during the last quarter. Institutional investors and hedge funds own 80.27% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.